Butterfly Network’s RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment
Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1, 2025
Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced that the European Commission has officially initiated the review and stakeholder consultation period for the Company’s request to revoke Annex IV n. 14 of the European Commission’s Restriction of Hazardous Substances (RoHS) Directive – a temporary exemption historically granted for lead in single crystal piezoelectric materials for ultrasonic transducers.
Following Butterfly’s revocation submission in October 2024, the Commission has now appointed the Oeko-Institut as consultant to lead the technical assessment of the request, including a third-party evaluation. The stakeholder consultation questionnaire is open and will run from June 6, 2025 to August 1, 2025, allowing interested parties to submit feedback. A recommendation by the Oeko-Institut to the European Commission on the request is expected by Q2 of 2026. If favorable and after final adoption of the Delegated Act indicating the change of scope in the exemption, it will take 12 to 18 months for it to enter into legal force.
“We’re encouraged to see that the formal review of our revocation request is underway and grateful to the Commission and the Oeko-Institut for their attention to this matter,” said Joseph DeVivo, President, CEO & Chairman of Butterfly. “We remain optimistic about the opportunity to align ultrasound manufacturing with the EU’s broader circular economy and sustainability goals and modernize standards that better reflect today’s innovations in medical imaging.”
Input from relevant stakeholders is welcomed as part of the consultation process. Registration to receive updates or to get involved can be accessed here: https://rohs.exemptions.oeko.info/index.php?id=4
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609884142/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 15:04:00 CEST | Press release
New platform unifies agents, models, knowledge, and data to finally deliver on the promise of AI as a transformative force for business Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. I
Capcom’s Resident Evil Requiem, the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 15:00:00 CEST | Press release
– The highly anticipated new installment to launch during the series’ 30th anniversary – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders9.6.2025 14:40:00 CEST | Press release
PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. This press release features multimedia. View the ful
Tier-1 MVNO Selects Tecnotree’s AI-Native BSS for Multi-Country Transformation Across UK & Europe9.6.2025 14:36:00 CEST | Press release
Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609328949/en/ This engagement will see the full-stack replacement of the MVNO’s legacy systems with Tecnotree’s composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent. The deploy
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic9.6.2025 14:00:00 CEST | Press release
Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609975546/en/ Glenn Crater, MD, FCCP, appointed Chief Medical Officer of Innospera Pharma Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom